MTOR and hepatocellular carcinoma: Veiga et al. (2018) investigated phenformin in hepatocellular carcinoma (HCC) and found that it induces mitochondrial fragmentation, a shift toward glycolysis, and sensitizes tumors to the dual inhibition of mTOR using allosteric (RAD001) and ATP-competitive (BEZ235) inhibitors.